26218-75-7Relevant articles and documents
A Family of Highly Emissive Lanthanide Complexes Constructed with 6-(Diphenylphosphoryl)picolinate
Bian, Zuqiang,Cai, Zelun,Huang, Chunhui,Liu, Jiajia,Liu, Zhiwei,Sun, Boxun,Tan, Yu,Wei, Chen,Wei, Huibo,Zhao, Zifeng
, (2020)
We report a novel family of lanthanide complexes Ln(DPPOP)3 (Ln = Pr, Nd, Sm, Eu, Tb, Dy, Er, and Yb) employing anionic tridentate (O∧N∧O) ligand 6-(diphenylphosphoryl)picolinate (DPPOP). Crystal structures of the complexes reveal that each lanthanide ion is nine-coordinated by three tridentate ligands. In the crystals, 1D channels are found, which can absorb and eliminate water reversibly. DPPOP possesses high triplet energy and can sensitize a series of lanthanide ions. An energy transfer mechanism is proposed through the higher excited states of the lanthanide ions. In the solid state, remarkably high quantum yields in the visible range are obtained: 81percent for Eu(III), 97percent for Tb(III), 13percent for Dy(III), and 4percent for Sm(III) complex.
Apoptosis signal regulating kinase inhibitor and application thereof
-
Paragraph 0037-0040, (2020/05/01)
The invention discloses an apoptosis signal regulating kinase inhibitor and an application thereof. The apoptosis signal regulating kinase inhibitor is a compound represented by general formula I, anda tautomer or a pharmaceutically acceptable salt thereo
FUSED BICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE
-
Paragraph 00176, (2019/03/05)
Fused bicyclic compounds and uses thereof in medicine. In particular, provided are fused bicyclic compounds used as ASK1 active regulator and and use of the compounds in the manufacture of a drug for treating a disease regulated by ASK1. Further provided are a pharmaceutical composition and a method of treating a disease regulated by ASK1 comprising administering the compounds or pharmaceutical composition thereof.
